APA (7th ed.) Citation

Hallqvist, A., Brynjarsdóttir, E., Krantz, T., Sjögren, M., Svensson, J., & Bernhardt, P. (2025). 177Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial. Journal of Nuclear Medicine, 66(5), 707. https://doi.org/10.2967/jnumed.124.268902

Chicago Style (17th ed.) Citation

Hallqvist, Andreas, Elva Brynjarsdóttir, Tomas Krantz, Marie Sjögren, Johanna Svensson, and Peter Bernhardt. "177Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial." Journal of Nuclear Medicine 66, no. 5 (2025): 707. https://doi.org/10.2967/jnumed.124.268902.

MLA (9th ed.) Citation

Hallqvist, Andreas, et al. "177Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial." Journal of Nuclear Medicine, vol. 66, no. 5, 2025, p. 707, https://doi.org/10.2967/jnumed.124.268902.